␥-Aminobutyric acid type A (GABA A ) receptors, a family of Cl
؊ -permeable ion channels, mediate fast synaptic inhibition as postsynaptically enriched receptors for ␥-aminobutyric acid at GABAergic synapses. Here we describe an alternative type of inhibition mediated by GABA A receptors present on neocortical glutamatergic nerve terminals and examine the underlying signaling mechanism(s). By monitoring the activity of the presynaptic CaM kinase II/synapsin I signaling pathway in isolated nerve terminals, we demonstrate that GABA A receptor activation correlated with an increase in basal intraterminal [Ca 2؉ ] i . Interestingly, this activation of GABA A receptors resulted in a reduction of subsequent depolarization-evoked Ca 2؉ influx, which thereby led to an inhibition of glutamate release. To investigate how the observed GABA A receptor-mediated modulation operates, we determined the sensitivity of this process to the Na-K-2Cl cotransporter 1 antagonist bumetanide, as well as substitution of Ca 2؉ with Ba 2؉ , or Ca 2؉ /calmodulin inhibition by W7. All of these treatments abolished the modulation by GABA A receptors. Application of selective antagonists of voltage-gated Ca 2؉ channels (VGCCs) revealed that the GABA A receptor-mediated modulation of glutamate release required the specific activity of L-and R-type VGCCs. Crucially, the inhibition of release by these receptors was abolished in terminals isolated from R-type VGCC knock-out mice. Together, our results indicate that a functional coupling between nerve terminal GABA A receptors and L-or R-type VGCCs is mediated by Ca 2؉ /calmodulin-dependent signaling. This mechanism provides a GABA-mediated control of glutamatergic synaptic activity by a direct inhibition of glutamate release.
GABA A 2 receptors, a large and diverse family of Cl Ϫ -permeable ion channels, mediate fast transmission at inhibitory GABAergic synapses and are critical for the development and coordination of neuronal activity underlying the majority of physiological and behavioral processes in the brain (1) (2) (3) . GABA A receptors are assembled from seven classes of homologous subunits, ␣(1-6), ␤(1-3), ␥(1-3), ␦, ⑀, , and (4), into heteropentamers that display extensive structural and functional heterogeneity at different subcellular localizations (5) . Thus, GABA A receptors also operate as tonically active extrasynaptic receptors (6 -8) , and as modulatory auto-or heteroreceptors present on axons and, in some instances, presynaptic nerve terminals in specific areas of the central nervous system (9, 10) .
Presynaptic inhibition mediated by GABA A receptors was first described in the spinal cord (11) (12) (13) (14) (15) . Recent electrophysiological studies have established the presence of presynaptic GABA A receptors in a number of brain regions, including cerebellum (16 -19) , hippocampus (20 -26) , auditory brainstem (27) , ventral tegmental area (28) , and others (9) . However, from these studies it is apparent that the presynaptic activity of GABA A receptors can have diverse effects on properties of neurotransmitter release, ranging from inhibition to stimulation of spontaneous or evoked release of neurotransmitters, depending on a type of nerve terminals, brain region, and/or the age of animals (9) . Given that neurotransmitter release results from a complex cascade of interactions between voltage-gated ion channels and protein machinery involved in synaptic vesicle exocytosis, and can be regulated at multiple points in this cascade (29) , it is important to establish the exact signaling mechanisms activated downstream of GABA A receptors to regulate this process.
We demonstrate here that GABA A receptors, by regulating intraterminal calcium concentration ([Ca 2ϩ ] i ), increase Ca 2ϩ / calmodulin-dependent signaling to inhibit subsequent voltagegated Ca 2ϩ entry and thereby suppress neurotransmitter release from glutamatergic terminals isolated from the adult rat neocortex. We demonstrate further that the inhibition of glutamate release requires NKCC1 activity, implicating a Cl Ϫ electrochemical gradient subserving a depolarizing activity of GABA A receptors in this preparation. Moreover, the modula-tion is dependent on the influx of Ca 2ϩ via L-or R-type VGCCs, although only R-type channels directly contribute to the release. The modulatory entry of Ca 2ϩ leads to the activation of calmodulin. Together, our results demonstrate GABA A receptor-mediated and Ca 2ϩ /calmodulin-dependent down-regulation of VGCCs leading to an inhibition of glutamate release from nerve terminals.
EXPERIMENTAL PROCEDURES
Preparation of Synaptosomes-Percoll gradient-purified synaptosomes were prepared as described previously (30) from the cerebral cortices of 2-month-old male Sprague-Dawley rats or from male wild-type or R-type (Ca V 2.3) ␣1E subunit-deficient (␣1E Ϫ/Ϫ ) mutant mice characterized previously (31) . On incubation at 37°C, synaptosomes show metabolic competence and ability to release neurotransmitters (32, 33) .
Glutamate Release Assay-Synaptosomes (0.1 mg) were resuspended in 1.5 ml of Hepes-buffered incubation medium (HBM: 140 mM NaCl, 5 mM NaHCO 3 , 1 mM MgCl 2 , 1.2 mM Na 2 HPO 4 , 10 mM glucose, and 20 mM Hepes, pH 7.4), and placed in an LS-5 spectrofluorimeter (PerkinElmer Life Sciences) at 37°C with stirring. Glutamate release was assayed in the presence of glutamate dehydrogenase (50 units/ml, Sigma), NADP ϩ (2 mM), and CaCl 2 (1 mM) by on-line fluorimetry, as described previously (32, 34) . Where indicated, synaptosomes were incubated in the presence of picrotoxin (50 -100 M, Tocris), SR 95532 (50 M, Tocris), strychnine (30 M, Sigma), bumetanide (10 M, Sigma), W7 (20 M, Tocris), or W5 (20 M, Tocris) for 10 min; -agatoxin IVA (100 M, Alomone Labs), -conotoxin GVIA (10 M, Alomone Labs), NiCl 2 (50 M, Sigma), nifedipine (1 M, Alomone Labs), or SNX-482 (100 nM, Alomone Labs) for 4 min; and muscimol (10 -500 M, Tocris) or isoguvacine (10 -500 M, Tocris) for 3 min prior to the addition of secretagogue. Other experiments were performed in the presence of EGTA (0.2 mM) for 7 min, followed by the addition of either BaCl 2 (1 mM) with/without muscimol (200 M) or only muscimol (200 M), and further incubated for 3 min prior to the addition of secretagogue. Release was stimulated as indicated with 4-aminopyridine (4AP, 1 mM), KCl (10 mM), or ionomycin (5 M), 10 min after the start of incubation and monitored at 2-s intervals. Data were analyzed using Lotus 1-2-3, Microcal Origin, and Microsoft Excel. Each n indicates the number of individual synaptosome preparations used; each preparation was derived from a single animal. Mean glutamate release Ϯ S.E. in the absence or presence of drugs is reported in time course traces. Unless otherwise indicated, mean release values Ϯ S.E. (nmol/mg protein/5 min) quoted in the text are levels attained at "steady state" 5 min after stimulation. Additionally, for some comparisons, the values obtained in the presence of drugs are expressed as percent of corresponding control values in the absence of drugs and shown as bar graphs. Statistical analysis was carried out using one-way ANOVA followed by post-hoc LSD test. Dose-response curves were fit using a sigmoidal relationship with variable slope employing GraphPad Prism.
Intraterminal Ca 2ϩ Measurements-Intraterminal Ca 2ϩ levels were assayed by on-line fluorimetry as described previously (33, 35) . Synaptosomes (0.1 mg) were resuspended in 1 ml of HBM containing CaCl 2 (0.1 mM) and loaded with Fura 2-AM (5 M) for 20 min at 37°C. Synaptosomes were washed with HBM by centrifugation, resuspended in 1.5 ml of HBM, and placed in an LS-5 spectrofluorimeter (PerkinElmer Life Sciences) at 37°C with stirring in the presence of CaCl 2 (1 mM). Synaptosomes were incubated for 3 min in the presence of muscimol (10 -500 M) prior to depolarization with 4AP (1 mM). Calibration procedures were performed as described previously (33) . Briefly, samples were alternately excited at ϭ 340 nm and ϭ 380 nm; fluorescence emission was monitored at ϭ 505 nm, and fluorescence ratios (excitation 340/380 nm) were calculated. The maximum fluorescence ratio (i.e. Ca 2ϩ -saturated Fura-2) was determined in the presence of 0.1% SDS and the minimum fluorescence ratio (i.e. Ca 2ϩ -free Fura-2) in the presence of 20 mM EGTA, added at the end of each experiment. Calculation of cytosolic [Ca 2ϩ ] i was carried out assuming a K d value for Fura-2 and Ca 2ϩ of 224 nM, using equations as described previously (36) . Cumulative data were analyzed using Lotus Drug Incubation and Immunoblotting-Synaptosomes were resuspended in HBM (at 1 mg/ml) in the presence of CaCl 2 (1 mM) on ice and placed at 37°C with stirring to start the incubation. As indicated in figure legends, synaptosomes were incubated with GABase (0.02-0.4 unit/ml), picrotoxin (1-100 M), or bicuculline (10 -100 M) for 10 min or in the presence of muscimol (10 -500 M) or isoguvacine (1-500 M) for 2 min before the lysis with 2% SDS. Protein concentrations were measured using the BCA assay (Pierce), with bovine serum albumin as standard. Equal amounts of protein were subjected to SDS-PAGE and transferred onto nitrocellulose membranes. Immunoblotting was carried out with a phosphorylation statespecific antibody that was raised to specifically recognize serine 603 (P-site 3) in synapsin I phosphorylated by Ca 2ϩ /calmodulindependent kinase (CaMK) II (anti-phospho (P)-site 3 synapsin I antibody, 0.5 g/ml) or with a total synapsin I antibody (0.5 g/ml, both kindly provided by Professors P. Greengard and A. C. Nairn, The Rockefeller University, New York). In additional immunoblotting experiments, antibodies specific for ␣1, ␣2, ␤3, ␥2, and ␦ subunits of GABA A receptors (kindly provided by Professor W. Sieghart, Vienna, Austria) were used as described (37) . Primary incubations were followed by incubation with 125 I-labeled protein A (0.05 Ci/ml; Amersham Biosciences). Blots were exposed to a PhosphorImager screen, and quantification of immunoblots was carried out using PhosphorImager scanning and ImageQuant software (GE Healthcare). Values stated are mean changes in phosphorylation (% of control) Ϯ S.E.
Immunohistochemistry-Immunofluorescence analysis was performed on neocortical slices as described previously (38, 39) . Sections were incubated with primary antibody solutions containing anti-P-site 3 synapsin I antibody (0.5 g/ml), antiglutamic acid decarboxylase (GAD) antibody (0.5 g/ml, Chemicon), and anti-vesicular glutamate transporter 1 (VGLUT1) antibody (0.2 g/ml, Chemicon), for 14 -16 h at 4°C. Sections were then washed (five times for 5 min) in phosphate-buffered saline and incubated in phosphate-buffered saline with 1% bovine serum albumin (w/v) containing a mixture of fluorescently tagged markers as follows: goat anti-rabbit IgG-Alexa 488, goat anti-mouse IgG-Alexa 555, and goat antiguinea-pig IgG-Cy5 (all diluted to 1:750; Chemicon). Immunoreactivity was visualized using a Zeiss LSM 510 Meta laserscanning confocal microscope. The estimation of the percentage of glutamatergic terminals positive for P-site 3 synapsin I was carried out in six randomly selected areas (324 m 2 ) in images acquired from neocortical layers I-III, layer IV, and layers V and VI.
RESULTS

Presynaptic GABA A Receptors Regulate Ca 2ϩ -dependent Phosphorylation of Synapsin I in Glutamatergic Nerve
Terminals-To detect the activity of GABA A receptors localized to nerve terminals in the rat neocortex independently from the large postsynaptic pool of these receptors, we isolated presynaptic nerve terminals (synaptosomes) using a well established procedure (30, 40, 41) . The presence of GABA A receptor ␣1, ␣2, ␤3, and ␥2 (short, s and long, l), and the absence of ␦ subunit, in a highly purified fraction of nerve terminals was detected by immunoblotting with subunit-specific antibodies (Fig. 1A, lane S) . We hypothesized that the activation of these receptors may regulate intraterminal Ca 2ϩ levels ([Ca 2ϩ ] i ) in a way similar to changes observed in mossy fiber terminals in the hippocampus (26) . To test this hypothesis, we monitored the effects of GABA A receptor activation or inhibition on the presynaptic CaMKII/synapsin I signaling pathway, using a phosphorylation state-specific antibody that recognizes synapsin I only when phosphorylated by CaMKII at Ser-603 (anti-P-site 3 synapsin I antibody, see Refs. 42, 43) . This is a highly sensitive biochemical reporter of changes in intraterminal [Ca 2ϩ ] i as synapsin I phosphorylation by CaMKII occurs specifically in response to depolarization-triggered Ca 2ϩ influx, as demonstrated previously (44) . Accordingly, in all synapsin I phosphorylation experiments, increases in anti-P-site 3 synapsin I in response to depolarization (4AP, 1 mM)-triggered Ca 2ϩ influx were monitored as positive controls (Fig. 1, B-F, lanes 4AP) .
We first tested whether activation of GABA A receptors with the agonist muscimol or isoguvacine stimulated CaMKII-dependent signaling in nerve terminals. Immunoblotting with anti-P-site 3 synapsin I antibody revealed a dose-dependent increase in CaMKII-dependent P-site 3 phosphorylation of synapsin I in the presence of muscimol (1-500 M), with 500 M agonist producing a 302.2 Ϯ 68.4% increase compared with controls (n ϭ 6, Fig. 1B , blot P-site 3 syn I and bar graph). Addition of isoguvacine (1-500 M) caused a similar dose-dependent stimulation of phosphorylation, with 50 and 500 M, respectively, effecting 385.4 Ϯ 132.5 and 670.7 Ϯ 263.7% increases compared with controls (Fig. 1C , panel P-site 3 syn I and bar graph). Neither agonist affected the total levels of synapsin I in these experiments (Fig. 1 , B and C, panel syn I).
Given the relatively high concentrations of GABA A receptor agonists required to produce the observed effects, we reasoned that high affinity GABA A receptors (45) may be tonically active, because the ambient concentration of GABA in our preparation has been estimated to be as high as 1-5 M (at 1 mg/ml concentration of synaptosomal protein) (46) . To reduce the levels of GABA, we incubated synaptosomes with increasing concentrations of GABase (a complex of GABA-aminotransferase and succinic semialdehyde dehydrogenase, 0.02-0.4 unit/ml) (47) . Immunoblotting with anti-P-site 3 synapsin I antibody revealed a significant dose-dependent decrease in CaMKII-dependent phosphorylation of synapsin I with increasing concentrations of GABase (0.02-0.4 unit/ml), reaching 59.8 Ϯ 7.7% of control in the presence of 0.4 unit/ml (Fig. 1D , panel P-site 3 syn I and bar graph), without any effect on the total levels of synapsin I (Fig. 1D, panel 
syn I).
To confirm that the observed regulation of presynaptic CaMKII/synapsin I signaling by ambient GABA was mediated by GABA A receptors, we incubated synaptosomes with increasing concentrations of picrotoxin (1-100 M), a GABA A receptor Cl Ϫ channel blocker, or bicuculline (10 -100 M), a competitive GABA A receptor antagonist. Immunoblotting with anti-P-site 3 synapsin I antibody revealed a dose-dependent decrease in basal levels of CaMKII-dependent phosphorylation of synapsin I, with statistically significant effects at 50 M (63.8 Ϯ 6.8% control) and 100 M picrotoxin Synapsins are presynaptic proteins expressed ubiquitously in all presynaptic nerve terminals in the central nervous system (48) . To determine whether the GABA A receptor-mediated regulation of synapsin I/CaMKII signaling cascade occurs universally throughout the rat neocortex (layers I-VI) or only in certain populations of nerve terminals, we carried out triple labeling immunocytochemistry, followed by confocal microscopy and colocalization analysis, using anti-P-site 3 synapsin I antibody (Fig. 2, A-C, in green) , together with anti-glutamic acid decarboxylase (GAD) antibody to identify GABAergic nerve terminals (Fig. 2, A-C, in red) , and antivesicular glutamate transporter (VGLUT) 1 antibody to identify glutamatergic nerve terminals (Fig. 2,  A-C, in blue) . Although terminalspecific staining was detected with all three antibodies, P-site 3 synapsin I was detected exclusively in a population of glutamatergic nerve terminals as reflected by the overlapping (green/blue) turquoise color and evidently absent from GABAergic terminals (Fig. 2, A-C, merged  images) . The quantitative analysis revealed the presence of P-site 3 synapsin I in 31.1 Ϯ 3.8% (layers I-III), 19.1 Ϯ 1.7% (layer IV), and 19.2 Ϯ 1.5% (layers V and VI) of glutamatergic nerve terminals in the neocortex. Complete lack of colocalization between GAD and VGLUT 1 confirmed the specificity of antibodies used in these experiments. These results, together with our biochemical experiments, are indicative of the presence of functional GABA A receptors specifically on a subset of glutamatergic nerve terminals in the rat neocortex.
Presynaptic GABA A Receptors Modulate Glutamate Release through Control of Depolarizationdependent Ca 2ϩ Influx-To determine whether presynaptic GABA A receptor activity regulates glutamate release, synaptosomes (0.1 mg/ml) were incubated in the presence of increasing doses of muscimol (10 -500 M) or isoguvacine (1-500 M), followed by the addition of 1 mM 4AP to trigger release. Control glutamate release (28.2 Ϯ 1.6 nmol/mg/5 min) was decreased in a dose-dependent manner by 200 M (21.8 Ϯ 1.6 nmol/mg/5 min, 77.2% of control) and 500 M (22.6 Ϯ 1.8 nmol/mg/5 min, 80.3% of control) muscimol (Fig. 3A) . Glutamate release (26.9 Ϯ 1.6 nmol/ mg/5 min in control) was also inhibited in a dose-dependent manner by 100 M (21.0 Ϯ 1.9 nmol/mg/5 min, 80.2% of control), 200 M (20.5 Ϯ 1.0 nmol/mg/5 min, 76.3% of con-trol), and 500 M isoguvacine (23.2 Ϯ 1.5 nmol/mg/5 min, 86.2% of control; Fig. 3B ). To confirm that the observed inhibition of 4AP-evoked glutamate release was indeed mediated by GABA A receptors, we incubated synaptosomes with 50 and 100 M picrotoxin (Fig. 3C ), or 50 M SR95531 (Fig. 3D) (Fig. 3H) . These data indicate that the ability of nerve terminals to undergo depolarization-dependent activation of Ca 2ϩ channels is significantly attenuated by prior GABA A receptor activity.
GABA ] i in some types of nerve terminals (49, 50) . Synaptosomes were incubated with bumetanide (10 M), a selective NKCC1 inhibitor, and glutamate release was triggered by the addition of 1 mM 4AP (Fig. 4A) extrasynaptic Ca 2ϩ prior to triggering glutamate release by the addition of 1 mM 4AP (in the presence of 1 mM Ca 2ϩ ; Fig. 4B ) (51) . In these experiments, although glutamate release per se (29.1 Ϯ 1.6 nmol/mg/5 min) was not altered, muscimol-dependent inhibition of release was completely abolished. The release measured with this protocol was 27.9 Ϯ 1.8 nmol/mg/5 min, similar to levels obtained in the absence of muscimol (Fig. 4B) . This indicates an obligate requirement for extrasynaptosomal Ca 2ϩ during the GABA A receptor-mediated modulation phase. Evidently the modulatory pathway needs to be activated prior to depolarization with 4AP, given that the presence of muscimol and Ca 2ϩ during depolarization as such (Fig. 4B ) is insufficient to produce an effect. This also implies that the GABA A receptor-mediated inhibition of glutamate release is contingent upon the activation of a long lasting Ca 2ϩ -dependent signaling mechanism.
We further investigated the signaling role of Ca 2ϩ in the observed GABA A receptor-mediated inhibition of glutamate release by measuring the effects of muscimol in the presence of 1 mM BaCl 2 release in the presence of Ba 2ϩ (Fig. 4C) . These results point to a key role of Ca 2ϩ -dependent activation of calmodulin downstream of presynaptic GABA A receptors.
To directly confirm that calmodulin is involved in GABA A receptor-dependent inhibition of glutamate release, we tested the effects of W7, a specific calmodulin inhibitor (55) . Under control conditions, glutamate release triggered by 1 mM 4AP (26.8 Ϯ 0.7 nmol/mg/5 min) was decreased to 21.4 Ϯ 0.8 nmol/ mg/5 min (79.9% of control) by muscimol (200 M, Fig. 4D ). In the presence of W7 (20 M), glutamate release was potently inhibited to 16.7 Ϯ 1.7 nmol/mg/5 min (62.3% of control release), but crucially, muscimol-induced inhibition of release was abolished (17.9 Ϯ 1.6 nmol/mg/5 min, 66.7% of control; Fig.  4D ). However, in the presence of W5, an analogue of W7 with ϳ10-fold lower affinity for calmodulin (56, 57) Fig. 4E ). This comparison of the structurally similar W7 and W5 indicates that it is the more potent anti-calmodulin activity of the former that abrogates the GABA A receptor-mediated modulation of release. These results emphasize that Ca 2ϩ mediates the observed GABA A receptor-dependent inhibition of glutamate release through the specific activation of calmodulin.
Specificity of VGCCs Involved in the GABA A Receptor-mediated Inhibition of Glutamate-Given that inhibition of glutamate release by presynaptic GABA A receptor activity requires an influx of Ca 2ϩ from the extracellular milieu, we applied selective VGCC inhibitors to characterize the role of individual Ca 2ϩ channel subtypes in this process. We started by investigating the role of N-, P-, and Q-type VGCCs, which are known to directly participate in triggering glutamate release from synaptosomes (58, 59) . To assess the role of P/Q-type VGCCs specifically, synaptosomes were preincubated with 100 M -agatoxin IVA (-Aga IVA) (60) . Glutamate release evoked by 1 mM 4AP (25.6 Ϯ 0.8 nmol/mg/5 min; Fig. 5A ) was significantly decreased in the presence of -Aga IVA alone (17.2 Ϯ 1.5 nmol/ mg/5 min, 67.2% of control release, or muscimol alone (19.5 Ϯ 1.5 nmol/mg/5 min, 76.2% of control release). However, in the presence of -Aga IVA, glutamate release was further inhibited by muscimol (12.1 Ϯ 1.6 nmol/mg/5 min, 70.3% of release in the presence of -Aga IVA alone; Fig. 5A ). The additive relationship between -Aga IVA and muscimol indicates that, although P/Q-type VGCCs contribute significantly to 4AP-evoked glutamate release, they appear not to mediate the modulatory effects of presynaptic GABA A receptors on glutamate release.
To block N-type VGCCs specifically, synaptosomes were preincubated with 10 M -conotoxin GVIA (-CTx GVIA) (61) . Glutamate release evoked by 1 mM 4AP (25.6 Ϯ 0.9 nmol/ mg/5 min; Fig. 5B ) under control conditions was significantly decreased in the presence of -CTx GVIA alone (21.4 Ϯ 1.3 nmol/mg/5 min, 84% of control) or muscimol alone (21.0 Ϯ 1.9 nmol/mg/5 min, 82.1% of control). Crucially, in the presence of -CTx GVIA, addition of muscimol caused a further inhibition of 4AP-evoked glutamate (17.1 Ϯ 1.4 nmol/mg/5 min, 67.3% of release in the presence of -CTx GVIA alone; Fig. 5B ), indicating that the modulatory influence of GABA A receptor-mediated inhibition of glutamate release is independent of N-type Ca 2ϩ channel activity, even though, similarly to P/Q type VGCCs, these channels are directly involved in mediating neurotransmitter release.
A potential role of T-type VGCCs in GABA A receptor-mediated modulation was tested in the presence of NiCl 2 , which selectively blocks these channels at the 50 M concentration used in our experiments (62, 63) . Glutamate release evoked by 1 mM 4AP (24.5 Ϯ 0.5 nmol/mg/5 min) under control conditions was unaffected by NiCl 2 (22.3 Ϯ 1.8 nmol/mg/5 min) indicating that T-type VGCCs do not directly support glutamate release from synaptosomes (Fig. 5C ). Muscimol (200 M) caused a significant inhibition of glutamate release (18.7 Ϯ 1.9 nmol/mg/5 min, 76.3% of control release) as shown earlier, but notably the modulation of glutamate release by GABA A receptor activation was unaffected by the presence of NiCl 2 (18.1 Ϯ 0.9 nmol/mg/5 min, 81.2% of NiCl 2 release; Fig. 5C ), indicating that T-type VGCCs, similar to P/Q-and N-type VGCCs, are not involved in the observed modulation of glutamate release by presynaptic GABA A receptors.
Next, the effect of inhibition of L-type VGCCs on the observed muscimol-dependent inhibition of release was investigated in the presence of 1 M nifedipine. Glutamate release triggered by 1 mM 4AP (24.9 Ϯ 1.5 nmol/mg/5 min) under control conditions was comparable with that obtained in the presence of nifedipine (27.9 Ϯ 2.6 nmol/mg/5 min; Fig. 6A ). Importantly, although control release was significantly inhibited by muscimol alone (200 M, 19.2 Ϯ 1.1 nmol/mg/5 min, 77.1% of control), this effect of GABA A receptor activation was abrogated in the presence of nifedipine, with release in presence of nifedipine and muscimol (25.0 Ϯ 1.5 nmol/mg/5 min; Fig. 6A ) being comparable with that in the presence of nifedipine alone. Thus, although presynaptic L-type VGCCs are not directly involved in triggering glutamate release (58, 59) , their activity appears critical for GABA A receptor-mediated inhibition of glutamate release.
Finally, the contribution of R-type VGCCs activity to muscimol-dependent inhibition of glutamate release was investigated using SNX-482 (100 nM), a toxin shown to specifically block ␣1E-subunit containing VGCCs at the concentration used in our assays (64) . Control glutamate release evoked by 4AP (25.2 Ϯ 1.7 nmol/mg/5 min) was reduced in the presence of SNX-482 (22.3 Ϯ 1.1 nmol/mg/5 min, 88.5% of control release), indicating that R-type VGCCs directly contribute to release of glutamate from synaptosomes. Although 4AP-evoked glutamate release was significantly reduced (20.4 Ϯ 1.4 nmol/mg/5 min, 81% of control release) in the presence of muscimol alone (200 M), this modulation was abolished by the addition of SNX-482, with the release measured in the presence of SNX-482 and muscimol (22.9 Ϯ 1.1 nmol/mg/5 min) being similar to that obtained in the presence of SNX-482 alone.
To authenticate the role of R-type VGCCs in the observed modulation of glutamate release by muscimol, we carried out experiments utilizing synaptosomes prepared from the neocortex of ␣1E subunit knock-out (␣1E Ϫ/Ϫ ) mice lacking the R-type VGCC activity (31) . In wild-type mice, glutamate release evoked by 1 mM 4AP under control conditions (35.5 Ϯ 1.3 nmol/mg/5 min) was significantly reduced by muscimol (200 M, 31.6 Ϯ 0.4 nmol/mg/5 min, 89% of control release in wildtype mice; Fig. 6C ). Glutamate release triggered by 1 mM 4AP was also significantly reduced in R-type knock-out mice (29.8 Ϯ 1.1 nmol/mg/5 min, 83.9% of the release in wild-type mice). However, the inhibition of release by muscimol observed in wild-type synaptosomes was completely abolished in synaptosomes isolated from R-type VGCC knock-out mice, with the release measured in the presence of muscimol (29.1 Ϯ 1.3 nmol/mg/5 min) being similar to that in the absence of muscimol (Fig. 6C) . Together, these experiments demonstrate a key role of R-type VGCCs as mediators of the presynaptic GABA A receptor-mediated regulation of glutamate release.
DISCUSSION
The data presented here reveal the presence and examine the function of presynaptic GABA A receptors in a population of glutamatergic nerve terminals in the adult rat neocortex. We demonstrate that nerve terminal GABA A receptors activate presynaptic Ca 2ϩ /calmodulin-dependent signaling to inhibit depolarization (4AP)-evoked Ca 2ϩ influx and glutamate release from isolated nerve terminals. This inhibitory action is dependent on the activity of the NKCC1 transporter, Ca 2ϩ and calmodulin, and the activity of L-and/or R-type VGCCs. Although both L-and/or R-type VGCC appear essential for modulation, they evidently play distinctive roles in this process given that, of the two, only R-type channels contribute directly to the release of glutamate.
We initially defined the presynaptic effects of GABA A receptors using Ca 2ϩ /calmodulin-dependent phosphorylation of synapsin I, as a direct and sensitive biochemical readout of alterations in intraterminal [Ca 2ϩ ] i (43, 65) . The synapsin family of small synaptic vesicle-associated proteins is ubiquitous throughout the central nervous system but is exclusively localized to presynaptic nerve terminals (66) . With this definitive presynaptic marker, we demonstrate that GABA A receptor activity increases basal intraterminal [Ca 2ϩ ] i , as reflected by increased CaMKII-dependent phosphorylation of synapsin I, whereas their inhibition produces a decrease in this parameter. Moreover, our immunohistochemical analysis to delineate this signaling revealed its exclusive localization to a subpopulation of glutamatergic terminals and its notable absence from GABAergic terminals, the latter finding being in agreement with the absence of Ca 2ϩ /calmodulin-dependent kinases and phosphatases at GABAergic synapses (67, 68) . Crucially, this analysis evinces GABA A receptors as modulatory heteroreceptors on ϳ20% of glutamatergic terminals in the rat neocortex.
The observed changes in intraterminal [Ca 2ϩ ] i suggest that nerve terminal GABA A receptors effect presynaptic depolarization rather than the hyperpolarization that is typical of postsynaptically localized receptors (1) . The functional outcome of GABA A receptor activation is predominantly determined by the Cl Ϫ electrochemical gradient established across the plasma membrane. This is in turn regulated by the activity of cation/ chloride cotransporters such as KCC2, which extrudes Cl Ϫ , and/or NKCC1, which transports Cl Ϫ into the cytosol (1). Whereas KCC2 is absent from presynaptic nerve terminals (69), NKCC1 has been implicated in the regulation of intraterminal [Cl Ϫ ] (49, 50), to achieve the high levels of 20 -22 mM (cf. somatodendritic compartment), directly measured in the calyx of Held (70) , pituitary terminals (71) , and retinal bipolar cell terminals (72) . In experiments reported herein, the inhibition of glutamate release by GABA A receptor agonists was highly sensitive to blockade of the cation/chloride cotransporter NKCC1. Together, the data suggest that high intraterminal [Cl Ϫ ] i , leading to the depolarization of nerve terminals by GABA A receptors, is of critical importance for the regulation of glutamate release by these receptors.
Whereas depolarizing effects of presynaptic GABA A receptors have been supported by electrophysiological evidence (1, 9) , the final functional outcome of their activity at the level of neurotransmitter release has been contentious given the conflicting reports indicating both stimulation and inhibition of release being mediated by GABA A receptors (9). As described here, inhibition of the evoked release by nerve terminal GABA A receptors has also been observed in the spinal cord (73), frontal cortex (74), hippocampus (20, 75) , suprachiasmatic nucleus (76), ventromedial hypothalamus (49), posterior pituitary (71, 77) , etc. Conversely, stimulation of spontaneous and evoked release of neurotransmitter by presynaptic GABA A receptors has been described in the cerebellum (18, 19) , hippocampus (21) (22) (23) (24) (25) , auditory brainstem (27) We elucidated the VGCC subtype(s) involved in the GABA A receptor invoked regulatory pathway by monitoring its sensitivity to VGCC subtype-specific antagonists added during the activation of GABA A receptors. Although blockade of P/Q-type (by -Aga IVA) or N-type (by -CTxGVIA) VGCCs reduces 4AP-evoked release substantially, conspicuously, the residual release in each case is still inhibited by GABA A receptor activation with muscimol. T-type VGCC block (by NiCl 2 ) had no effect on evoked release or the inhibition thereof by prior muscimol treatment.
In contrast, L-type VGCC block by nifedipine abolished the inhibition of glutamate release produced by muscimol (note nifedipine has no effect on glutamate release in control conditions). Although L-type VGCCs are mainly located at the soma and dendrites (78) , Ca 2ϩ influx through these channels during repetitive stimulation has been implicated in regulation of GABA release from cultured GABAergic neurons, presumably through a presynaptic localization and operation (79) . More directly, L-type VGCCs also appear to be present in mossy fiber terminals where they mediate large Ca 2ϩ currents (80) . It is therefore feasible that depolarizing action of nerve terminal GABA A receptors initiates a long lasting Ca 2ϩ -dependent regulatory mechanism following L-type VGCC activation.
Finally, we examined the role of R-type VGCCs in the observed regulation using both pharmacological blockade by SNX-482, and by the genetic ablation of the ␣1E channel subunit in mice (31) . In both these models, the inhibition of glutamate release by muscimol was abolished. Thus, together with L-type VGCCs, R-type VGCCs are implicated in the modulation of release produced by presynaptic GABA A receptor activation.
A key question arising is: what is the Ca 2ϩ -dependent mechanism invoked by presynaptic GABA A receptors to inhibit glutamate release? Our observations that GABA A receptordependent inhibition of release is ablated by the inhibitor W7, but unaffected by its inactive analogue W5, clearly implicates calmodulin as a modulatory player. The effects of Ca 2ϩ /calmodulin on the observed regulation could operate at any number of loci in the release cascade. Judging from the lack of GABA A receptor-mediated regulation of release when ionomycin is used as the secretagogue, involvement of targets downstream of Ca 2ϩ entry is obviated. This leaves potential regulation at the level of Ca 2ϩ entry or upstream at loci controlling nerve terminal excitability.
Direct inhibitory action of GABA A receptor-mediated Ca 2ϩ entry on VGCCs themselves is a tenable possibility given that all the high threshold VGCCs have been shown to be subject to Ca 2ϩ /calmodulin-dependent inactivation (CDI) (81) (82) (83) (84) (85) . If VGCCs are indeed direct targets for GABA A receptor-mediated inhibition, R-type VGCCs surface as the only feasible targets given our data showing that P/Q-and N-type VGCC blockade is of no consequence to the regulation seen, and L-type VGCCs do not support release. These observations not only support R-type VGCCs as key players in the regulation seen, but they obviate the possibility that GABA A receptor-dependent regulation impinges upstream at the level of channels regulating nerve terminal excitability, as such an action would then be predicted to equally affect all release-supporting VGCCs.
There are increasing examples of R-type VGCCs supporting neurotransmitter release in the calyx of Held (86) , glutamatergic transmission in the rat hippocampus (87) and in oxytocin secretion in neurohypophysial terminals (88) . Our data with ␣1E-subunit knock-out mice now show that there is significant support of glutamate release by these VGCCs. The question as to whether direct CDI of R-type VGCCs underlies the GABA A receptor-mediated inhibition is more open. This is because CDI is generally short lived, yet the regulation of release by muscimol is long lasting because it evidently occurs/persists for some time after initiation of Ca 2ϩ /calmodulin-dependent signaling. Moreover, CDI per se would also invoke P/Q-and N-type VGCCs in the regulation, which we observe clearly not to be the case. An alternative possibility is that the Ca 2ϩ /calmodulin-dependent regulation impinges on R-type VGCC activity indirectly, by mediating activation of a phosphorylation or dephosphorylation cascade. Interestingly in this regard, in the dendritic spines of the CA1 pyramidal cells, L-type VGCC-mediated elevations of Ca 2ϩ are suggested to activate CaMKII (and/or Ca 2ϩ -dependent adenylyl cyclase), which then leads to a relatively long lived depression of R-type VGCCs (89) . Similarly, in GABAergic terminals projecting to Meynert neurones, L-and R-type VGCCs collaborate in mediating spontaneous and evoked neurotransmitter release, respectively (90) . A tenable hypothesis arising from the present data would be that GABA A receptor-mediated depolarization leads to presynaptic L-type VGCC-mediated activation of Ca 2ϩ / calmodulin-dependent signaling, which subsequently effects depression of Ca 2ϩ entry through R-type VGCCs during the release of glutamate. This hypothesis is consistent with the abolition of GABA A receptor-mediated inhibition of glutamate release following the pharmacological block of L-or R-type VGCCs, or deletion of the ␣1E-subunit underpinning R-type Ca 2ϩ conductance. Together, our results demonstrate that nerve terminal GABA A receptors play an important and specific role in the regulation of glutamate release from a population of glutamatergic nerve terminals in the neocortex. Thus GABA A receptors may instigate a powerful activity-dependent presynaptic control of excitatory synapses, and as such, they represent a novel functional target for a plethora of GABAergic pharmacological agents.
